Sector News

Reuters: Rare disease drugmaker PTC Therapeutics explores sale – sources

February 25, 2015
Life sciences
(Reuters) – Rare disease drugmaker PTC Therapeutics Inc (PTCT.O) is exploring a potential sale amid takeover interest from several pharmaceutical companies, including Shire Plc (SHP.L) and BioMarin Pharmaceutical Inc (BMRN.O), according to people familiar with the matter.
The company, which treats a muscle-wasting disorder known as Duchenne, is working with financial advisers as it weighs strategic alternatives, said the sources, who asked not to be named because the matter is private.
Representatives for South Plainfield, New Jersey-based PTC Therapeutics could not be reached for comment. Representatives for Shire and BioMarin declined to comment.
The stock of PTC Therapeutics, which has a market valuation of roughly $2 billion, rose as much as 25 percent to $68.44 on reports of the potential sale, before easing to $63.51, up 15.1 percent.
Makers of treatments for rare diseases, also known as orphans, are attractive acquisitions for large pharmaceutical companies looking to offset a drop in sales as patents on their blockbuster products expire.
Prosena Holding NV, which also makes a treatment for Duchenne, was acquired last November by BioMarin for $840 million.
PTC Therapeutics’ drug Translarna has received orphan drug status in the European Union and the United States and is in process of seeking U.S. Food and Drug Administration approval.
Shire Plc could be interested in acquiring PTC Therapeutics to add to its portfolio of rare disease drugs, the sources added.
Shire has made several acquisitions to bolster its focus on rare diseases, including a $5.2 billion purchase of NPS Pharmaceuticals in January and a $4.2 billion deal for ViroPharma last year.
It also took a look at acquiring Salix Pharmaceuticals Ltd (SLXP.O) in recent weeks but ended up passing on the deal, according to sources.
(Reporting by Olivia Oran and Soyoung Kim in New York; Editing by Christian Plumb and Jeffrey Benkoe)

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]